NCT04143477View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

peficitinib

Oral

Trial Locations (1)

Unknown

Site CN86001, Beijing

All Listed Sponsors
lead

Astellas Pharma China, Inc.

INDUSTRY

NCT04143477 - A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter